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Abstract
Background: Spontaneous preterm deliveries that occur before the 34th week of gestation, and particularly before the 
32nd week of gestation, have been strongly associated to intrauterine infection, ascending from vagina, and represent 
the largest portion of neonatal deaths and neurological problems. Bacterial vaginosis, characterized by a diminished or 
absent flora of lactobacilli and increased colonization of several anaerobic or facultative microorganisms, increases two 
times the risk of preterm delivery before the 34th week. Trials of antibiotics failed to show efficacy and effectiveness 
against spontaneous preterm birth related to bacterial vaginosis. Some studies indicate benefit from selected 
probiotics to treat genitourinary infections, including bacterial vaginosis.
Objective: The purpose of this study is to evaluate the effectiveness of the early administration of selected probiotics 
to pregnant women with asymptomatic bacterial vaginosis/intermediate degree infection to reduce the occurrence of 
spontaneous preterm delivery and related neonatal mortality and morbidity.
Methods/Design: Women attending public prenatal care services in Rio de Janeiro will be screened to select 
asymptomatic pregnant women, less than 20 weeks' gestation, with no indication of elective preterm delivery. Those 
with vaginal pH > = 4.5 and a Nugent score between 4 and 10 (intermediate degree infection or bacterial vaginosis) 
will be randomized to either the placebo or the intervention group, after written informed consent. Intervention 
consists in the use of probiotics, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14, 2 capsules a day, each 
capsule containing more than one million bacilli of each strain, for 6-12 weeks, up to the 24th-25th wk of gestation. 
Ancillary analyses include quantification of selected cervicovaginal cytokines and genotyping of selected 
polymorphisms. The randomization process is stratified for history of preterm delivery and blocked. Allocation 
concealment was designed as well as blinding of women, caregivers and outcome evaluators. The study will be 
supervised by an independent monitoring committee. Outcomes under study are preterm delivery (< 34- < 32 weeks 
of gestation) and associated neonatal complications: early neonatal sepsis, bronchopulmonary dysplasia, 
periventricular leukomalacia, necrotizing enterocolitis, and prematurity-related retinopathy; definitions were adapted 
from those recommended by the 2002 version of the Vermont-Oxford Network. Trial registration at NIH register: 
NCT00303082.
1- Introduction (Scientific background and 
explanation of rationale)
In the United States, where prematurity rates are higher
than those in Western Europe, nearly 11% of babies are
born premature and preterm delivery is associated to
approximately 80% of fetal, neonatal and infants' deaths
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[1]. Studies in Brazilian urban areas indicate a prematu-
rity rate above 10% - as high as the American rate [2,3].
About 25% to 30% of preterm deliveries occur due to
medical indication and the remaining percentage occurs
spontaneously [1-4]. Neonatal mortality and morbidity
risks are inversely associated to gestational age at birth;
spontaneous preterm deliveries that occur before the
35th week of gestation, and particularly before the 32nd
week of gestation, have been strongly associated to intra-
uterine infection. [5,6].
Approximately half of the neurological disabilities
found in children, including cerebral palsy, are attributed
to prematurity; those disabilities limit the learning capa-
bilities and social abilities during childhood and adult life
and imply a significant overload for their families and for
society. The subgroup of babies born before the 32nd
week of gestation, which corresponds to around 2% of
those born alive, represents the largest portion of deaths
and neonatal neurological problems [5,6].
The cost of taking care of premature children in devel-
oped countries is very high [7]; in developing countries,
like Brazil, the problem is composed by a low effective-
ness of the assistance provided in nurseries, mainly that
rendered in NICUs.
Important risk factors to spontaneous preterm delivery,
such as age < 18 years, race, education, and bacterial vag-
inosis are associated with low social-economic level. The
most important factor in spontaneous preterm delivery
(SPTD), history of preterm delivery, increases 3 times the
risk of a subsequent preterm delivery and is probably
associated to underlying risk factors [4,8,9].
Among risk factors that could be modified, bacterial
vaginosis (BV), an infectious condition, is the most
important. Bacterial vaginosis is present in 15-20% of
normal pregnant women in developed countries [8], and
this proportion almost doubles in high-risk populations
[10]. Studies conducted with pregnant and non-pregnant
women suggest that BV in the lower genital tract is asso-
ciated to infection of the upper tract by BV microorgan-
isms; this could result in the inflammation of the decidua
and chorio-amnion and cause subsequent preterm deliv-
ery as well as fetal and neonatal infection [5,6].
BV increases two times the risk of preterm delivery
before 35th weeks' gestation [8]. Prematurity thus origi-
nated increases the probability of certain complications,
such as early sepsis, bronchopulmonary dysplasia,
periventricular leukomalacia and necrotizing enterocoli-
tis [11-14], which may cause the referred long term dis-
abilities as well as death.
Bacterial vaginosis (BV) is a modification of the vaginal
flora characterized by a diminished or absent flora of lac-
tobacilli, which increases the vaginal pH, and a signifi-
cantly increased colonization of several anaerobic or
facultative microorganisms, mainly Gardenerella vagina-
lis, Prevotella sp, Bacteroides sp, Mobiluncus sp, gram
positive cocci, and genital mycoplasma (Mycoplasma
hominis and Ureaplasma urealyticum). Bacterial vagino-
sis is a condition in which there are no parabasal cells and
leukocytes are rare, in a similar way to what occurs in
women whose mucosa is normal [15].
Although BV is the most prevalent vaginal disorder in
adult women in the world, its pathogenesis is still not
clear. In most cases, the condition is asymptomatic; the
vaginal secretion presents scarce inflammatory signs,
with very few leukocytes. That is why the term used to
define the condition is "vaginosis" and not "vaginitis" [15].
The reason why most women who have BV do not pres-
ent inflammatory signs, even in the presence of abnormal
flora, is unknown yet. To understand the response of vag-
ina l i m m unit y t o m i cr ob ia l in vas io n m a y  be  crucia l t o
avoid adverse results associated to bacterial vaginosis
(BV).
The Nugent method is a standardized method, rela-
tively simple and inexpensive, designed to evaluate bacte-
rial vaginosis. It requires Gram-staining the vaginal
smear and was developed to obtain an objective and
reproducible laboratorial test, thus differing from the tra-
ditional Amsel method, which includes clinical criteria.
The Nugent score classifies the vaginal flora according to
the semi-qualitative presence of lactobacilli, Gardenerella
vaginalis and bacteria similar to Gardenerella (such as
Prevotella, Bacteroides and Porphyromonas sp), and
Mobiluncus sp. It is highly associated to BV clinical signs
and vaginal pH [16,17]. It also provides a gradation of dis-
turbances of the vaginal flora: a Nugent score from 0 to 3
indicates a normal flora; from 4 to 6 indicates an interme-
diate flora and from 7 to 10 indicates BV [16].
The relatively low sensitivity of BV tests for premature
birth, close to 30% (both Amsel's and Nugent's), is similar
to the performance of other screening tests for spontane-
ous premature birth in asymptomatic women, such as the
Bishop test, cervical ultrasound and fetal fibronectin [18].
Their sensitivity is relatively low according to some
cohort studies and large case-control studies; an
improved performance can be obtained in populations at
higher risks [8-19].
It is important to note that the so-called intermediate
level (Nugent score 4-6) presents risk for premature birth
close to that of BV (score 7-10) [20,21]. The inclusion of
the intermediate degree apparently increases significantly
the sensitivity of the method, without extra costs, while
providing an earlier detection of the vaginal disturbance.
Elevated vaginal pH and neutrophils are strongly asso-
ciated to early spontaneous preterm birth [22]. On the
other hand, data published by a large study showed that
the use of the vaginal pH < 4.5 as a cutoff point to prelim-
inarily sort pregnant women, between the 8th and the
22nd weeks, brings about the exclusion of around 40% ofKrauss-Silva et al. Reproductive Health 2010, 7:14
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asymptomatic women and one third of the spontaneous
preterm births less than 32 and also less than 35 weeks,
although almost 50% of the remaining (non excluded
population, 60%) is classified between 0-6 [21].
Assuming that: a) the sensitivity of the Nugent test is
around 50% (BV + Intermediate stage), b) the change of
the vaginal ecosystem that results in BV directly affects
the vaginal pH (reduction of lactobacilli), one of its classi-
cal markers, and c) the determination of the vaginal pH is
simple, immediate and relatively cheap, the proposal of
using the vaginal pH as a pre-screening step of the
Nugent test seems justified as a way to increase the effi-
ciency of the whole screening process.
The association between infections of the upper uri-
nary tract with preterm delivery (premature birth) in BV
asymptomatic women supported the trials on antibiotics
to prevent preterm delivery in these women. But the
results of these trials were contradictory [23-25]. To
resolve these contradictions, NIH/DHSS (USA) produced
a well designed large trial on the subject. Nevertheless, its
results did not show any trend whatsoever of benefit
towards antibiotic-therapy (metronidazole associated to
erythromycin). Besides, the study showed negative
results in the subgroup of patients with history of pre-
term delivery [26]. Those results could be attributed, in
part, to bacterial resistance, to the timing of the interven-
tion (possibly too late), to the toxicity for the fetus; it
could also be partially due to a particular form of inflam-
matory process apparently associated to BV [27-29].
Thus, when examining interventions to prevent pre-
term delivery associated to intrauterine infection, origi-
nated from bacterial vaginosis, it is important to consider
an alternative that might overcome the limitations of
antibiotic-therapy, as mentioned above. The so-called
probiotics, a kind of bacteriotherapy, has been studied
lately and is the object of the present study.
Probiotics have been tested for treating infectious,
inflammatory and allergic conditions, mainly those that
occur in the intestinal, genitourinary and respiratory
tracts [30,31]. One of the important preliminary steps of a
trial of probiotics is the previous design/selection of the
bacteria (probiotics) to be tested, based in requirements
deemed as essential [32].
Some studies indicate that selected probiotics are effi-
cacious against moderate urogenital tract infections,
including BV [33-38]. Nevertheless, there is no evidence
of the effectiveness of probiotics for BV related condi-
tions like preterm birth and neonatal morbidity.
Invasive mechanism and causative role of intrauterine 
infection
Microorganisms may reach the amniotic cavity and the
fetus, generally, by ascending from the vagina and bottom
of the uterus, according to hystological and microbiologi-
cal studies. Some bacteriae are more frequently isolated
from the amniotic cavity of women in preterm labor and
whose membranes are intact: Ureaplama urealyticum,
Fusobacterium spp and Mycoplasma hominis. Other
organisms associated to bacterial vaginosis, such as
Streptococcus agalactiae, Gardenerella vaginalis and Bac-
terioides spp, were also found. So far , there is no out -
standing evidence that viruses might be linked to the
genesis of preterm delivery [5,6].
Studies on biological markers of intrauterine and intra-
amniotic infection such as FNF and interleukin-6, are
consistent with histological and microbiological observa-
tions: it takes an average of 7 or 8 weeks for a preterm
delivery, sepsis or fetal/neonatal death to occur, after a
positive test. Such evidence as a whole suggests that the
sub-acute inflammatory process is associated with spon-
taneous abortion and preterm delivery [5].
Therefore, existing evidence supports a role of intra-
uterine infections in significant causes of spontaneous
premature birth and fetal and neonatal infections, thus
fulfilling the requirements of biological plausibility, tem-
poral relation, consistency and force of association, gradi-
ent dosage-response and specificity.
Intrauterine infection may not result however in pre-
mature birth and often it does not; this would indicate
that the fetus or the pregnant woman has dealt with the
infection in order to continue the pregnancy, regardless
of the fact that the infectious process has not been cured.
M o s t  p a t i e n t s  p r e s e n t i n g  w i t h  a s y m p t o m a t i c  B V  g o
through a regression process that takes several weeks, to
normal vaginal conditions [10].
The general consensus on the host and microbial inter-
actions in the genital tract is that systemic immunity does
not perform a dominant role, but the immunoregulatory
mechanisms of the local response do. The vagina is dif-
ferent, to a certain degree, from other human mucosal
surfaces because this niche must be tolerant with xenobi-
otic molecules (gestation) [15].
Simhan et al [27] proposed a model to explain the link
between inflammatory response and modifications of
cervicovaginal ecosystem and the clinical picture. In this
model, the existence of individualized patterns of immu-
nological response leads to different types of evolution,
that is: when pregnant women are hypo-respondent, the
immune response would not be able to control bacterial
infection and patients would be predisposed to ascending
intrauterine infections. In the opposite case, of a hyper
response, development of an exaggerated inflammatory
response would occur, with symptoms of vaginitis which
could result in preterm births. The ideal response would
be the development of an inflammatory response propor-
tional to the severity of the aggression.
An immunomodulatory role has been proposed for IL-
10 along with a call for the examination of not only pro-Krauss-Silva et al. Reproductive Health 2010, 7:14
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inflammatory but also anti-inflammatory cytokines and
associated genetic polymorphisms to differentiate
between hyper- and hyporesponders [39].
Hypo-response
Cauci et al [15,40,41] observed that the innate response of
the vaginal mucosa of women with BV, which should
result in the proliferation of neutrophils, generally does
not occur. Epithelial cells produce cytokine IL 1B but the
production of IL8 (induced by IL 1B), that, on its turn,
induces production of neutrophils, is prevented by
hydrolitic enzymes and by proteolytic enzymes (sialidases
and prolidases) produced by the BV bacteria. Cauci et al
[40-42] also observed that the presence of those enzymes
in the vaginal fluid, accompanied by (in interaction with)
an elevated pH (that fosters the activity of these enzymes)
increases more than ten times the risk of premature birth.
M o r e o v e r ,  S i m h a n  e t  a l  [ 2 7 ]  o b s e rv e d  t h a t  p r e g n a n t
women with low levels of IL-1B, IL6 and IL 8 cytokines in
the cervical fluid, obtained between the 8th the 20th
week, are more susceptible to developing clinical choro-
amnionitis.
Regarding the immunospecific response, Cauci et AL
[43] found out that part of the women that have BV do
not produce a specific answer to BV agents. One of the
reasons for this hypo-answer is the extensive degradation
of Ig A and Ig Ms developed by the sialidases produced by
BV bacteria, high levels of sialidases appears to be associ-
ated with resistance to antibiotic therapy for BV or with
early reinfection [41,44].
Hyper-response
Several studies investigated the role of hyper-responsivi-
ness in the genesis of spontaneous preterm delivery. They
observed that the increase of cytokines, typically related
to inflammatory processes in the mucosa of the cervico-
vaginal area, is linked to invasion of the lower and upper
gynecological tract by atypical bacteria, and is associated
to preterm delivery [24,27,45-47].
The increase of those cytokines has also been associ-
ated to serious neonatal damages: pneumonia, sepsis,
necrotizing enterocolitis, periventricular leukomalacia,
periventricular bleeding, cerebral palsy and bronchopul-
monary dysplasia [14,48,49]. The study conducted by
Genc et al [50] showed association of high concentration
of IL-1B with preterm birth. It also found an even higher
association of a low ratio IL-1ra (natural antagonist of the
IL 1B)/IL 1B, that is, a high concentration of "free" IL-1B,
with preterm delivery. It also observed a high sensitivity
(78%) of the IL ratio - 1ra/IL-1B - in predicting preterm
delivery.
Those findings are being complemented by studies
about genes involved in the inflammatory reactions
related to the ascending vaginal infections that precede
preterm delivery. A study conducted by Macones et al
[51], in the USA, found high association of the rare allele
of the TNF gene (TNF2) - that modulates inflammatory
processes towards hyper-response - with preterm deliv-
ery, and a powerful multiplicative interaction (OR = 6; p =
0.007) of that allele with bacterial vaginosis (symptom-
atic). Moreover, Simhan et al [52,53] found that a poly-
morphism of TNF (-308) is associated with
chorioamnionitis, and a polymorphism of the promoter
of interleukin 6 (-174) is associated with spontaneous
preterm delivery; black pregnant women lacked the pro-
tective allele related to IL-6. A similar but more compre-
hensive study was conducted with Australian women
[54].
The above studies suggest that it might not be appro-
priate to exclude but to treat and then include pregnant
women with vaginal symptoms of infection in trials of
interventions to avoid preterm delivery [28]. Maternal
and fetal polymorphisms associated to hypo- response
have not been clearly identified.
Probiotics: basic concepts
Some studies have demonstrated that the microbiological
environment may overcome the marked virulence of a
given bacterial strain in causing the disease, indicating
that the importance of environmental factors is inter-
twined with the issue of microbial replication. The exoge-
nous or endogenous bacteria that carry pathogenic pre-
requirements must have replication dominance so that
the disease occurs. The acknowledgement that a micro-
bial species can inhibit a different type of microbe has
provoked interest in exploring this phenomenon for the
wellness of human beings [55]. By definition, probiotic
bacteria are live microbes and have beneficial effects on
human health [30,56].
The correction of properties of a non balanced indige-
nous microbiota - in this case, manipulation of vaginal
microbiota in order to interrupt the infectious/inflamma-
tory ('allergic') process that leads to preterm delivery -
constitutes the rationale of probiotic therapy. Some stud-
ies indicate that a transient colonization may be impor-
tant and sufficient since the non-balanced microbiota can
be corrected by a short probiotic intervention [30] and
this may be relevant in the case of BV during pregnancy.
Due to the poly-microbial nature of BV, cure, treatment
and control of recurrence are more complex processes
than those related to diseases caused by a single infec-
tious agent [57].
The evidence that lactobacilli protect against vaginal
infections because they produce lactic acid and therefore
maintain a pH higher than 4.0-4-5 have been established
long ago. Furthermore, lactobacilli inhibit the growth of a
large number of opportunist vaginal microorganisms,
including E.coli, Candida albicans, G.vaginalis, andKrauss-Silva et al. Reproductive Health 2010, 7:14
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Mobiluncus sp, because they produce hydrogen peroxide
(H2O2), which further decreases vaginal pH, as well as
other inhibiting metabolites [42,57].
Moreover, many of the probiotic effects are not related
to changes in microbiota only, as indicated by cultures.
Actually, an important part of the beneficial effects of
probiotics is related to its immunomodulating effects:
increase in immunologic activity as well as of anti-inflam-
matory activity [30].
Studies on the intestinal microbiota, for example, indi-
cate that it provides immunomodulation of the inflam-
matory activity, thus avoiding aberrations that might lead
to disease. A healthy homeostasis might be attained by
optimizing the balance between pro and anti-inflamma-
tory cytokines. The effects of tolerance (toleragenic) of
the intestinal flora may be mediated by the production of
regulatory T cells (T and T helper), that characterize the
intestinal immunological system and induce suppressing
cytokines that fight hypersensitivity and inflammation
[30].
However, uncertainties about the mechanisms involved
in vaginal immunity and on the set of metabolic charac-
teristics of the bacteria to be used as probiotics, add diffi-
culties to design effective and safe interventions, related
not only to BV, but also to the outcomes preterm delivery
and neonatal morbidity [57].
Design/development of the alternative probiotics: criteria 
and studies related to the biological plausibility that 
probiotics may specifically cure the condition Bacterial 
Vaginosis and may prevent spontaneous preterm birth
Some studies focus on attributes considered biologically
desirable for probiotics to treat the BV condition. These
attributes, which may turn a probiotic effective to treat
BV, have been tested in vitro and in vivo, using some spe-
cific probiotics, as detailed ahead.
Women whose vagina is colonized by lactobacilli that
produce H2O2 have less possibility of developing vagino-
sis. The maintenance of vaginal pH close to 4.0, through
the production of lactic acid and H2O2, is essential for
vaginal health. The production of H2O2 is thus consid-
ered an important characteristic of a lactobacilli strain
intended to become a probiotic in the BV condition.
S tudies in vivo demonstra t ed adhesive pot ential to the
urogenital epithelium of some strains [36,37]; an in vitro
study showed greater or lesser adhesion to vaginal epithe-
lium for as little as 60 species studied [59]. When lactoba-
cilli are introduced orally, they may move from the
rectum to the vagina within one week [35]. Studies in
vitro, using molecular typing, observed the permanence
of exogenous lactobacilli for several weeks after being
introduced [57,58].
The ability of probiotic lactobacilli strains to induce
apoptosis of bacteriae they are competing against to get
nutrients (growth antagonism) and for vaginal niche col-
onization (adherence to vaginal epithelial cells and multi-
plication), as well as to escape the immune response of
the host, added to/through their potential of producing
H 2 O 2 ,  m u s t  b e  c o n s i d e r e d  a s  p a r a m e t e r s  t o  s e l e c t
strains. Not all lactobacilli strains, producers of H2O2,
are capable of effectively colonizing vaginal niches [57].
The exclusion by apoptosis of BV bacteria was shown in
in vivo studies for some lactobacilli strains [57,58], as well
as the in vitro and and in vivo growth inhibition of BV
bacteriae, in a more or less intense way [57-59], the pro-
duction of H2O2 in vitro and in vivo [36,59]. Reid consid-
ers the possibility that the apoptosis/displacement of
bacteriae may also happen through immunomodulation
[33].
Other attributes, characteristics and additional meta-
bolic mechanisms, often associated to the previously
mentioned abilities, are also relevant to increase the
chance of a probiotic changing into normal the vaginal
microecology of a flora associated to bacterial vaginosis.
The production of bacteriocins that inhibit the synthesis
of enzymes by BV bacteria, the already mentioned siali-
dades and prolidases - that are markers of virulence -is
one of the important generic attributes of these probiot-
ics.
For example, an important metabolic characteristic of a
probiotic is its ability to inhibit excessive production of
poliamines by BV bacteriae, that is, to present increased
activity of the enzyme arginine deiminase. When this
enzyme (bacteriocin) deprives the environment of argin-
ine, it propitiates the colonization of lactobacilli - foster-
ing the apopotosis of anaerobic bacteriae -, it inhibits the
growth of these bacterie and the consequent inflamma-
tory activity [57]. The clinical recovery of patients with
BV, after the intake of a specifc lactobacilli strain with
increased activity of the enzyme arginine deiminase, was
observed along with a progressive decrease in the con-
centration of poliamines in the vaginal secretion [57].
The importance of the degree to which the referred
attributes are present for the efficacy of a probiotic is still
not clear [58,59]. In general, the studied lactobacilli
strains are not homogeneous regarding those attributes.
The production of H2O2 and that of the specific bacteri-
ocin arginine deiminase, for example, are mutually exclu-
sive. Such observations by different studies have resulted
in the consensus that a probiotic must have more than
one strain of lactobacilli that are complementary as to
requirements considered fundamental [36,57,59].
Another research group that focuses on the question of
hyper-response suggests that lactobacilli must show anti-
TH2 activity in order to counterpoise/avoid "allergic"
answers. Pochard et al [60] observed anti-TH2 activity in
lactobacilli strains tested in vitro, which inhibited the
production of cytokines that characterize the allergicKrauss-Silva et al. Reproductive Health 2010, 7:14
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reaction of the respiratory tract (IL4 e IL5). This ability of
lactobacilli has not been tested yet regarding the BV con-
dition.
Safety of probiotics
Besides the already mentioned desirable attributes of an
anti BV probiotic - adherence to the epithelial cells of the
vagina, apoptosis of pathogenic microbes, production of
H2O2 and of bacteriocins antagonistic to the growth of
atypical microorganisms, as well as anti-TH2 activity - a
probiotic must be safe.
Lactobacilli and bifidobacteriae are, in principle, con-
sidered to be safe because they are components of the
comensal human flora and due to the fact that they have
been used for a long time in food industry and in
d o u c h e s ,  e v e n  b y  p r e g n a n t  w o m e n ,  w i t h o u t  h a r m f u l
effects [31,56,58].
Although lactobacilli have been identified in blood cul-
tures and cultures of other organs, infections by lactoba-
cilli are rare (30). Positive hemocultures for lactobacilli
occurred in 0.24% of patients in a Finish study and in 0.1%
in French patients; the infections occurred in patients
with immunodeficiency [31,32]. The induction of infec-
tion has already been directly or indirectly tested by sev-
eral studies on probiotics and none of the strains caused
morbidity [58].
Evidence found by trials on the effectiveness and safety of 
tested lactobacilli against BV
The choice of a probiotic, like that of any medical tech-
nology, requires that its effectiveness and safety are veri-
fied and so, the evaluation of these attributes, conducted
by clinical trials _ preferably those randomized, con-
trolled and double-blind_ is an important requirement
for its regular use in human beings.
Summary of trials available on the subject
a. Reid et al, 2001 [35] - Prospective study with a group of
10 asymptomatic women, with history of recurrent uro-
genital infection, including 6 asymptomatic cases of
intermediate degree infection/BV, treated with an oral
solution containing selected lactobacilli (Lactobacillus
rhamnosus GR-1 e Lactobacillus fermentum TC-14),
twice a day, for 14 days. No adverse side effects were
reported and adherence to treatment was considered
excellent. The 6 asymptomatic cases of intermediate
degree infection/BV were cured after the first week of
treatment and remained normal during follow-up
(between 1 and 3 months).
b. Reid et al, 2001b [37] - Randomized controlled trial,
comparing 4 probiotics: 3 of them were formed of 2
selected lactobacilli strains (Lactobacillus rhamnosus
GR-1 and Lactobacillus fermentum TC-14) in different
dosages: 1 dosage (2 groups), 2 dosages (1 group); the 4th
group was considered the placebo because the lactobacilli
used had no outstanding properties. Sixty percent (60%)
of women presented BV or intermediate degree infection;
1/3 of them presented BV at the beginning of the study.
Forty-two (42) asymptomatic women were randomized;
the technician that evaluated the Nugent was blinded, as
well as the researchers and the patients, except those
receiving 2 daily dosages. Probiotics were orally taken
(capsules) for 28 days. No adverse side effects were
reported and adherence to treatment was considered
excellent. The results were favorable to probiotics as
compared to placebo; the best results against BV were
observed in the group of patients who received 2 dosages
a day (close to 90% effectiveness for BV). These results
remained unchanged for a month after the treatment had
finished.
c. Reid et al, 2003 [34] - Randomized, double-blind pla-
cebo-controlled trial (patients and researchers) to test the
safety and prevention/treatment of asymptomatic uro-
genital infections, including BV. A population of 64
asymptomatic women in their fertile years used, once a
day, a capsule with 2 types of selected bacilli (Lactobacil-
lus rhamnosus GR-1 and Lactobacillus fermentum TC-
14), with a concentration of each bacillus per capsule
superior to 1 million or of placebo, for 60 days. The
adherence of patients was considered excellent. Patients,
monitored throughout the study, did not report side
effects. Close to 40% of the cases of asymptomatic BV
improved (they became intermediate stage) at the end of
treatment, in comparison with 13% of the placebo group
(p = 0.02). There was also significant reduction in the
presence of Monilia and of E.coli in the group treated,
versus the placebo group. However, the efficacy
decreased after a 30 day-follow up.
d. Shalev, 2002 [38] - Randomized controlled trial, with
crossover, comparative of the ingestion of yogurt contain-
ing lactobacilli acidophilus and pasteurized yogurt, in a
total of 46 women for prophylaxis of recurrent BV. Signif-
icant statistical increase was observed as to the number
of lactobacilli acidophilus in the vaginal mucosa and also
a significant statistical decrease of BV cases (p < 0.001)
occurred during the period of treatment with lactobacilli,
as compared to the period when groups ingested pasteur-
ized yogurt.
The above studies _small but consistently in favor of
lactobacilli probiotics _ indicate that the ecologic treat-
ment of BV through the colonization of vagina by exoge-
nous lactobacilli is an alternative worth trying, both for
BV and preterm delivery. However, the effectiveness of
probiotics regarding the consequences of BV, i.e., preterm
delivery and neonatal morbidiy, although plausible, has
n o t  bee n  r e po rt ed  y e t.  I t  is  i m po rta n t  t o  r e m a r k  t h a t,
despite the fact that none of the mentioned trials enrolled
pregnant women, Lactobacilli rhamnosus have been usedKrauss-Silva et al. Reproductive Health 2010, 7:14
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in a controlled clinical trial in pregnant women [61], side
effects not being observed.
On the other hand, the probability of a test yielding
benefits for health depends on the frequency of the prob-
lem, the ability of the test to detect the condition and to
what extent early treatment is better than late interven-
tion [62]. The lead time (time lapse between the detection
and the moment in which the condition to be avoided
might have occurred without the screening) needed to
change favorably the natural history of a problem, varies
in different diseases, different cases and depends on the
treatment [63].
In this project, it is assumed that the necessary lead
time to prevent spontaneous preterm delivery, associated
to infection, depends on the moment (gestational age) at
which vaginal infection occurs, on the kind of infection
and on the mother (fetus)'s response to it, as well as on
the moment the test is conducted regarding the develop-
ment of the ominous infectious/allergic process and on
the ability of the treatment to subdue the infection at the
occasion (timing) it is conducted.
Thus, the rationale for the trial is based on the hypothe-
ses that: a) the observed lack of efficacy of antibiotics
may, in part, be attributed to lead time - the intervention
would have occurred too late _, in part to bacterial resis-
t a n c e ,  i n  p a r t  t o  t o x i c i t y  o f  t h e  a n t i b i o t i c s  u s e d  a n d ,
finally, in part, to an inflammatory process similar to
allergy [27-29], and b) probiotics have more favorable
attributes (bacteriotherapy plus immunomodulation)
and, supposedly, less adverse events, to deal with bacte-
rial vaginosis and preterm delivery, provided that they are
given within an adequate lead time and dosage for an
effective intervention.
2. General Objectives
To estimate the effectiveness of the early administration
of specially formulated probiotics to pregnant women
with bacterial vaginosis or an intermediate degree infec-
tion to prevent the occurrence of spontaneous premature
birth and related neonatal mortality and morbidity.
2.1. Specific objectives
a- To assess the presence of bacterial vaginosis and inter-
mediate degree infection in asymptomatic pregnant
women, with no risk/indication of elective preterm deliv-
ery, admitted to prenatal care after the 8th and before the
20th week of gestation.
b- To investigate whether the study intervention can
lower the vaginal pH and the Nugent score.
c- To asses the effectiveness of an early intervention
with special probiotics to treat bacterial vaginosis/inter-
mediate infection and to prevent spontaneous preterm
delivery and associated neonatal/infant conditions in
positive women, according to item a, by conducting a
controlled, randomized, double-blind trial.
d- To analyze the association between the concentra-
tion of selected cytokines at cervicovaginal mucosa and
the Nugent score, and the < 34 weeks' gestation prematu-
rity rate, in both study subgroups.
e- To analyze the association of selected genetic poly-
morphisms and the occurrence of a) bacterial vaginosis
or intermediate degree infection and b) preterm birth, in
both study subgroups.
3. Methods
Asymptomatic pregnant women, admitted after the 8th
and before the 20th week of pregnancy in selected public
prenatal care services, in the city of Rio de Janeiro, will be
evaluated to identify a) excluding clinical conditions,
mainly those related to the presence of pathological con-
ditions associated with elective preterm delivery, to
symptomatic vaginal conditions and to current, or within
the past two weeks, use of antibiotic therapy and b) preg-
nant women with previous history of preterm delivery.
Gestational age will be determined by the date of the last
menstrual period and through ultrasound results, the last
one being privileged. Women who test positive to syphi-
lis, toxoplasmosis, gonorrhea and HIV will be excluded.
Other absolute exclusion criteria are: multiple gestation,
istmo-cervical incompetence (cerclage in current gesta-
tion), fetus with major congenital malformations in cur-
rent gestation, insulin dependent diabetes mellitus,
systemic arterial hypertension under medication, antibi-
otic therapy after the 8th week of the current gestation,
clinical suspicion of low urinary tract infection, chronic
asthma requesting intermittent therapy, continuous or
recent corticotherapy (up to one month), hemolytic peri-
natal disease; systemic eritematous lupus. Relative exclu-
sion criteria, i.e, only if observed at the moment of the
evaluation, are: bacterial vaginosis or tricomoniasis with
laboratory confirmation, HPV (those with macroscopic
lesions in the genitalia or microscopic pre-cancerous
lesions).
After written informed consent, vaginal pH assessment
will be performed; patients with a pH < 4.5 will be
excluded. Then, cervicovaginal smear will be obtained to
evaluate the presence of BV or intermediate degree infec-
tion, using the Nugent method. Women with a Nugent
score under 4 will be excluded from the trial.
Ancillary analyses
Vaginal fluid and oral mucosa samples will also be
obtained to allow for the evaluation of selected cytokines
(IL-1beta, IL-1ra, IL-6, IL-8 and IL-10) and related
genetic polymorphisms, respectively, from women with a
pH> 4.4 who have consented. Furthermore, vaginal
smear, cervicovaginal fluid and oral samples will be col-Krauss-Silva et al. Reproductive Health 2010, 7:14
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lected from a subsample of the women with a pH < 4.5 for
comparison purposes. Gram-stained vaginal smears will
be further analysed to determine the number of leuko-
cytes per epithelial cell and the proportion of parabasal
epitheliocytes to allow for the detection of moderate or
severe aerobic vaginitis.
3.1. Randomization process
It was stratified for the factor history of preterm delivery
(HPD), and blocked by using a permuted block design.
Stratified randomization was attained by producing one
blocked and randomized list for each stratum. Blocks of
size 8 were specified for the strata of non HPD; for the
group of HPD, blocks of size 4 have been adopted. The
sequence for randomization was electronically generated
by an independent research assistant.
Women with a Nugent score between 4 and 10 will be
randomized, after a second written informed consent, as
soon as possible. Research nurses responsible for alloca-
tion are not directly involved with prenatal care, i.e., with
clinical screening. Allocation will be concealed by sealing
both placebo and intervention capsules, identical in
aspect, in sequentially numbered identical containers
according to the allocation sequence. Besides the preg-
nant women, doctors/nurses and researchers/evaluators
(assessment of outcomes, including Nugent score and
other lab procedures) are to be blinded to the randomiza-
tion process.
The trial will test two lactobacilli strains, Lactobacillus
rhamnosus GR-1 and Lactobacillus fermentum RC-14,
the latter presently denominated Lactobacillus reuteri
RC-14, developed and studied by Reid et col [33-36] as
earlier mentioned. Each capsule contains an amount
superior to one million bacilli of each strain. Each partici-
pant will receive, from the research nurse, one box with
six bottles, box and bottles equally numbered, of probiot-
ics/placebo, each bottle containing 30 capsules, corre-
sponding to a maximum intervention period of 12 weeks.
Participants will be then instructed to maintain the box at
the refrigerator (not at the freezer) and to take two cap-
sules per day, along a period that may vary from six to
twelve weeks, depending on the participant's gestational
age at the moment of enrollment in the study. Enrolled
women will be free to contact the research assistant
nurses or the research doctor; one week after randomiza-
tion, they will be contacted by telephone for information
about treatment. More detailed questioning will be made
at each routine prenatal visit until the completion of the
trial (around the 24-25th week of gestation) regarding
adhesion/adherence, adverse events and clinical intercor-
rences, according to a previously designed form. Adher-
ence will be fostered, when appropriate. At the post
treatment prenatal care visit, randomized women will be
asked to bring back all bottles; capsules remaining in the
bottles they return will be counted. Adherence is defined
as at least 6 wks of treatment.
At the post-treatment prenatal care visit, vaginal pH
will be assessed; cervicovaginal smear and fluid will be
collected to determine the post intervention Nugent
score and levels of the selected cytokines in order to eval-
uate changes in those parameters (secondary results).
A detailed and extensive protocol was developed. Stan-
dard Operational Procedures were elaborated to cover
the logistics and operational aspects of the trial. They
cover not only details related to the whole screening pro-
cess and materials' collection, transportation and storage
but also elements that are relevant to the randomization
process, including creation and protection of the alloca-
tion sequence, labeling of bottles and boxes, as well as the
filling in and sending out the Case Record Forms.
A special software has been developed to acquire and
store collected information. A workshop for training pur-
pose and a pilot study were carried out in each of the ser-
vices involved in the study; the protocol was revised
accordingly.
Patients flow in accordance to the protocol is summa-
rized in Figure 1.
The outcomes to be studied will be preterm delivery <
34 and < 32 weeks of gestation and associated morbidity
and mortality: early neonatal sepsis, bronchopulmonary
dysplasia, periventricular leukomalacia, necrotizing
enterocolitis, and prematurity-related retinopathy. Defi-
nitions of these conditions are similar to those used by
the Vermont-Oxford Network, published in 2002.
A more detailed account of selected procedures and
definitions is presented below.
3.2. Laboratory Methods
Measurement of vaginal pH
Vaginal pH will be measured by a strip with discrimina-
tion of 0.5, to evaluate women with pH higher than or
equal to 4.5 and higher than or equal to 5.
Collection of clinical specimen for bacteriological analysis
Nugent Method - A swab will be used to obtain a cervico-
vaginal smear that will be Gram stained to be examined
and interpreted according to the criteria described by
Nugent, Krohn and Hillier [16]. A complementary analy-
sis of the vaginal smear will be performed (400 × magnifi-
cation, phase contrast microscope): the determination of
the number of leukocytes per epithelial cell and the pro-
portion of parabasal epitheliocytes to allow for the detec-
tion of moderate and severe aerobic vaginitis [64].
Quantitative tests of cervicovaginal cytokines
Cervicovaginal fluid will be collected by using 2 Dracon
swabs (Fisherland, Fisher Scientific, Pittsburgh, PA,
USA). Each swab will be placed in the vagina and cervical
os for 10 seconds, thus reaching saturation. Next, each of
them will be placed in a polypropylene plastic tube con-Krauss-Silva et al. Reproductive Health 2010, 7:14
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taining tampon-saline phosphate (PBS). The material will
be stored at -20C. The quantification of the selected
inflammatory cytokines (IL-1beta, IL-1ra, IL-6, IL-8 and
IL-10) will be conducted by an immunoenzymatic test of
capture or "sandwich-type" test, using R & D Systems, or,
if possible, a special LUMINEX platform in order to
broaden the spectrum of cytokines to be analyzed.
Genetic polymorphisms detection
A swab of the oral mucosa will be obtained and the DNA
will be extracted by the conventional procedure [64]. Rel-
evant single nucleotide polymorphisms will be investi-
gated for TNF, IL-1beta, IL-1ra, IL-6 e IL-10. They will be
genotyped with the PCR and sequence specific primers
(PCR-SSP).
3. 3. Criteria to Diagnose Neonatal Morbidity
The criteria used to identify study morbidty were adapted
from those defined by the Vermont Oxford Network in
2002.
- Early neonatal sepsis (72 h) - blood for the leuko-
gram should be obtained during the first 72 hours; 
diagnosis will be reached by analyzing the neutro-
philic index (ratio between immature neutrophils/
total neutrophils). Diagnosis will also be done in case 
of positive hemoculture.
- Periventricular leukomalacia -evaluation will be 
conducted in newborns less than 32 weeks' gestation 
by performing a transfontanel ultrasound. To be con-
sidered cystic periventricular leukomalacia, multiple 
small periventricular cysts must be identified.
- Bronchopulmonary dysplasia - evaluation should be 
conducted in newborns less than 32 weeks' gestation, 
using the criteria of a) suggestive X-Ray and b) new-
born need of any supplemental oxygen on the date of 
week 36, gestational age.
- Necrotizing enterocolitis - evaluation should be 
conducted in newborns with less than 34 weeks, using 
both clinical and radiographic criteria.
- Newborn retinopathy - evaluation will be conducted 
by a neonatologist trained in performing indirect 
ophthalmoscopy in newborns. The exam will be real-
ized at 4 weeks after birth in newborns less than 1500 
g.
3.4. Sample size
The estimation of the sample was based on the following
information:
a) international and national data (very scarce) on the 
incidence of, and microorganisms associated with 
bacterial vaginosis and intermediate degree infection 
in pregnant women, taking into consideration differ-
ent concepts and degrees of severity of those condi-
tions and also, different populations and techniques 
Figure 1 Flow diagram according to the trial protocol.
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used to identify and evaluate it [21,23,24] as well as 
the probabilities of natural recovery from vaginosis 
[10];
b) an estimate of the intersection of intermediate 
degree/BV scores and pH cutt off point (4.4), i.e., the 
percentage of pH positive (> 4.4) asymptomatic preg-
nant women who present a normal (0-3) Nugent 
score);
c) an estimate of the percentage of spontaneous pre-
term delivery expected in the placebo group [21,25];
d) an estimate of the effectiveness of probiotics to be 
tested in the study.
An initial loss, close to 20% of the pregnant women
admitted for routine prenatal care, was supposed to occur
due to the clinical exclusion criteria. The use of the vagi-
nal pH < 4.5 parameter as a cutoff point to sort the preg-
nant women in whom the Nugent test will be performed,
would bring about the exclusion of around 40% of the pH
tested women; it also would imply the loss of one third of
the less than 34 week spontaneous preterm deliveries
expected to occur in the population that passed the clini-
cal screen, although around 45% of Nugent score of the
remaining population (after clinical and pH screens)
would fall between 0-6 [25].
On the other hand, for that remaining population, the
estimated incidence of BV plus intermediate degree
would be 85%, which would result in the exclusion of
around 15% of the population that passed the clinical and
pH screens [25]. Therefore, the combination of the pH
and Nugent criteria was expected to exclude near 50% of
the pregnant women who passed the clinical screen; it
also would imply the loss of about 20% of the less than 34
week spontaneous preterm deliveries expected to occur
in the population that passed the clinical, pH and Nugent
screens. The rate of spontaneous preterm deliveries < 34
weeks was estimated to be 6% in the placebo group and
close to 3% in the intervention group, i.e., efficacy was
supposed to be 50%; for spontaneous preterm deliveries
under 32 weeks, the corresponding estimates would be
close to half of those percentages.
Based on a significance level of 0.05 and a 80% power to
show differences in rates of less than 34 week spontane-
ous preterm deliveries, the population to be randomized
was estimated to be 1500 pregnant women (to show 50%
efficacy regarding spontaneous preterm deliveries less
than 34 weeks gestation). Taking into consideration the
previous losses plus 5% refusals to give written informed
consents as well as 15% loss related to adherence to treat-
ment, a sequence of nearly 3500 pregnant women shall be
screened in order to obtain the desired sample.
3.4. Data analysis
A post randomization table will comprehend the distri-
bution of all relevant variables. Outcomes will be ana-
lyzed according to intention to treat and effective
treatment. The Student t test, the X2 test for proportions
and the Fisher test will be used in the preliminary data
analyses. In those cases where the Student test does not
apply due to non Gaussian distribution, the Mann-Whit-
n e y  t e s t  w i l l  b e  u s e d .  O u t c o m e s  w i l l  a l s o  b e  a n a l yz e d
according to subgroups of selected risk factors at admis-
sion and categories of severity of the infectious process,
according to the study biological markers. The associa-
tion between knowledge based selected factors and
dichotomous or continuous outputs will be investigated
under the framework of generalized additive models to
handle non linear predictors as well as non Gaussian
responses.
3.5. Ethical issues
The trial was approved by an Institutional Review Board
and by the National Review Board (CONEP). The trial
will be monitored by an independent data monitoring
committee.
The trial conduction will follow ICH/GCP Regulation
and the local regulation for clinical trials.
3.6. Registration
The study has been registered at the NIH register plat-
form; its identifier is NCT00303082. The study has
recently finished recruiting patients.
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